Cue Biopharma Stock Quote CUE - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.7796

Bid

0.74

Ask

0.799

Volume

233,341

0.7351 Day's Range 0.80

0.7301 52 Week Range 4.375

Market Cap

37.922M

Previous Close

0.7701

Open

0.78

Last Trade

200

0.7796

(formt)

Last Trade Time

Financial Volume

$ 176,913

VWAP

0.758175

Average Volume (3m)

405,292

Shares Outstanding

48,643,316

Dividend Yield

PE Ratio

-0.71

Earnings Per Share (EPS)

-1.04

Revenue

5.49M

Net Profit

-50.73M

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant ... Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cuebiopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Cue Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CUE. The last closing price for Cue Biopharma was $0.77. Over the last year, Cue Biopharma shares have traded in a share price range of $ 0.7301 to $ 4.375.

Cue Biopharma currently has 48,643,316 shares outstanding. The market capitalization of Cue Biopharma is $37.46 million. Cue Biopharma has a price to earnings ratio (PE ratio) of -0.71.

Form 4 - Statement of changes in beneficial ownership of securities

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.1793	-18.6985087079	0.9589	0.975	0.7301	345136	0.83861688	CS
4	-0.6804	-46.602739726	1.46	1.58	0.7301	610659	1.08470009	CS
12	-0.6204	-44.3142857143	1.4	2.26	0.7301	405292	1.39193731	CS
26	-2.1104	-73.0242214533	2.89	2.93	0.7301	321666	1.66712695	CS
52	-3.5954	-82.1805714286	4.375	4.375	0.7301	330704	2.20989955	CS
156	-9.7204	-92.5752380952	10.5	18.42	0.7301	313429	4.81545214	CS
260	-6.3804	-89.1117318436	7.16	35.5	0.7301	298125	9.01313912	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF	20.10 (839.25%)	128.82k
RGCRegencell Bioscience Holdings Ltd	$ 15.15 (349.55%)	1.34M
ATPCAgape ATP Corporation	$ 0.2262 (58.18%)	107.32M
SLRXSalarius Pharmaceuticals Inc	$ 2.34 (51.95%)	60.04M
GSUNGolden Sun Health Technology Group Ltd	$ 7.46 (45.42%)	590.09k
FLYEFly E Group Inc	$ 1.1601 (-81.82%)	25.44M
RNAZTransCode Therapeutics Inc	$ 0.3035 (-61.70%)	9.78M
JAGXJaguar Health Inc	$ 1.755 (-58.90%)	15.47M
MIRAMIRA Pharmaceuticals Inc	$ 2.55 (-49.10%)	25.64M
IVPInspire Veterinary Partners Inc	$ 5.19 (-43.83%)	1.67M
SLNASelina Hospitality PLC	$ 0.026 (-29.73%)	220.33M
SPWRSunPower Corporation	$ 0.9514 (32.91%)	186.76M
NVDANVIDIA Corporation	$ 122.59 (-0.77%)	173.91M
ADILAdial Pharmaceuticals Inc	$ 1.3422 (26.62%)	160.04M
HOLOMicroCloud Hologram Inc	$ 0.588 (26.07%)	135.56M